Table 3 Baseline characteristics before and after IPTW adjustment (percent distributions)
Characteristics | †Percent distribution | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Before adjustment | After IPTW adjustment | ||||||||||||
Losartan | Valsartan | Telmisartan | Candesartan | Olmesartan | p value | Losartan | Valsartan | Telmisartan | Candesartan | Olmesartan | p value | ||
Age (years, mean ± SE) | 60.1 ± 0.8 | 63.4 ± 0.8 | 63.2 ± 0.9 | 63.2 ± 0.6 | 61.2 ± 0.9 | 0.0084* | 63.4 ± 0.8 | 62.7 ± 0.8 | 63.4 ± 0.9 | 62.4 ± 0.6 | 62.9 ± 0.9 | 0.8485 | |
Men | 52.8 | 64.7 | 61.1 | 59.4 | 66.2 | 0.0394* | 60.0 | 61.2 | 59.3 | 60.9 | 55.8 | 0.7809 | |
Medical History | |||||||||||||
Cerebrovascular disease | 28.5 | 32.3 | 34.1 | 29.5 | 24.5 | 0.2667 | 28.5 | 31.0 | 32.5 | 29.3 | 30.1 | 0.9066 | |
Ischemic heart disease | 32.7 | 35.0 | 37.3 | 36.7 | 26.0 | 0.0917 | 30.1 | 34.0 | 35.4 | 34.7 | 30.8 | 0.6735 | |
Other heart disease | 25.2 | 28.2 | 23.2 | 25.8 | 25.5 | 0.8313 | 26.7 | 26.3 | 25.1 | 25.7 | 23.3 | 0.9434 | |
Malignant neoplasm | 48.6 | 51.1 | 47.0 | 55.0 | 54.7 | 0.2735 | 52.0 | 52.0 | 52.6 | 52.4 | 52.1 | 0.9999 | |
Thyroid disease | 35.5 | 29.3 | 36.2 | 32.5 | 35.9 | 0.4354 | 31.6 | 32.0 | 34.0 | 33.8 | 35.0 | 0.9302 | |
Rheumatoid disease | 26.2 | 12.4 | 18.9 | 14.9 | 9.9 | <.0001* | 17.5 | 14.5 | 15.8 | 16.4 | 16.0 | 0.9361 | |
Liver disease | 51.9 | 55.6 | 53.5 | 57.9 | 54.2 | 0.6296 | 52.8 | 55.3 | 57.0 | 54.5 | 53.5 | 0.9303 | |
Kidney disease | 59.4 | 49.6 | 62.7 | 49.3 | 46.9 | 0.002* | 47.7 | 52.1 | 54.3 | 52.6 | 51.8 | 0.7232 | |
Hyoerlipidemia | 59.8 | 62.8 | 60.5 | 62.7 | 58.9 | 0.8559 | 58.3 | 61.0 | 61.1 | 60.7 | 61.8 | 0.9594 | |
Proteinuria | 44.9 | 36.8 | 38.4 | 37.1 | 38.0 | 0.3621 | 38.5 | 37.5 | 35.5 | 38.5 | 41.8 | 0.7941 | |
Current Medication | |||||||||||||
Oral hypoglycemic drugs | 21.5 | 29.3 | 33.5 | 28.2 | 35.9 | 0.0155* | 31.0 | 30.7 | 28.8 | 28.6 | 29.9 | 0.9614 | |
Immunosuppressive drugs | 7.5 | 2.3 | 3.2 | 2.4 | 2.6 | 0.0077* | 3.7 | 2.6 | 3.7 | 3.1 | 2.7 | 0.9372 | |
Lipid-lowering drugs | 40.2 | 37.2 | 35.1 | 40.0 | 35.9 | 0.6958 | 35.1 | 39.0 | 39.0 | 39.0 | 38.1 | 0.8877 | |
Statin | 32.2 | 28.2 | 28.7 | 29.3 | 27.1 | 0.8211 | 27.3 | 30.2 | 29.6 | 29.5 | 28.6 | 0.9659 | |
Fibrate | 2.8 | 4.1 | 3.2 | 5.7 | 4.2 | 0.4381 | 3.1 | 4.2 | 4.8 | 4.5 | 4.8 | 0.8962 | |
Other lipid-lowering drugs | 9.8 | 6.8 | 7.0 | 9.2 | 6.8 | 0.5729 | 8.3 | 8.9 | 9.2 | 8.2 | 7.0 | 0.9402 | |
Thyroid drugs | 3.7 | 1.9 | 3.2 | 3.5 | 1.0 | 0.3284 | 2.6 | 2.2 | 2.7 | 3.1 | 2.7 | 0.971 | |
Antipsychotic drugs | 10.3 | 4.1 | 3.2 | 5.0 | 3.7 | 0.007* | 5.7 | 3.8 | 4.1 | 4.6 | 7.2 | 0.5156 | |
Antithrombotic drugs | 33.6 | 32.7 | 34.1 | 29.0 | 22.9 | 0.0783 | 27.7 | 30.7 | 30.6 | 30.0 | 29.6 | 0.9579 | |
Chemotherapeutic drugs | 1.4 | 3.4 | 2.2 | 4.6 | 2.1 | 0.1554 | 3.1 | 3.1 | 4.9 | 3.3 | 3.1 | 0.8304 | |
Liver disease therapeutics | 7.0 | 3.8 | 2.2 | 3.3 | 6.8 | 0.0405* | 4.4 | 4.2 | 3.0 | 3.8 | 5.4 | 0.834 | |
CKD therapeutic drugs | 2.8 | 0.0 | 0.0 | 0.4 | 0.0 | 0.0003* | 0.6 | 0.0 | 0.0 | 0.9 | 0.0 | 0.236 | |
Steroids | 18.7 | 8.7 | 13.0 | 10.7 | 6.8 | 0.0012* | 9.7 | 10.1 | 11.4 | 10.6 | 10.7 | 0.9859 | |
NSAIDs | 38.3 | 36.1 | 30.8 | 28.8 | 27.1 | 0.0347* | 29.8 | 32.1 | 32.7 | 31.2 | 31.1 | 0.9771 | |
Proton pump inhibitors | 22.0 | 12.8 | 18.9 | 15.9 | 18.2 | 0.087* | 18.1 | 17.5 | 16.2 | 16.9 | 19.6 | 0.9208 | |
H2 blockers | 22.4 | 14.3 | 14.1 | 16.4 | 12.0 | 0.0395* | 14.9 | 15.6 | 19.1 | 15.9 | 18.4 | 0.7162 | |